<?xml version="1.0" encoding="UTF-8"?>
<p>In a phase II trial, 50 patients with metastatic melanoma at stage IIIC or IV were enrolled [
 <xref rid="B124-biomedicines-08-00060" ref-type="bibr">124</xref>]. Systemic treatment was carried out for 74% of the patients with advanced melanoma. Patients were injected with 10
 <sup>6</sup> pfu/mL, and the dose was increased 3 weeks later to 10
 <sup>8</sup> pfu/mL. Treatment continued every 2 weeks for a maximum of 24 treatments [
 <xref rid="B124-biomedicines-08-00060" ref-type="bibr">124</xref>]. TVEC was again well tolerated and the toxicity was primarily narrowed to flu-like symptoms and local inflammation. The overall survival rate was 58% at one year and 52% at two years [
 <xref rid="B9-biomedicines-08-00060" ref-type="bibr">9</xref>].
</p>
